Castle Biosciences price target raised to $39 from $37 at Baird

Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Castle Biosciences (CSTL) to $39 from $37 and keeps an Outperform rating on the shares. The firm said they reported a solid 3Q, with revenue in-line and encouraging OpEx leverage. Overall volumes grew, though dermatology volumes were below estimates due to seasonality, and TissueCypher again demonstrated compelling momentum.